Spinal Cord Injury Market Report and Forecast 2024-2032
Description
Spinal Cord Injury Market Report and Forecast 2024-2032
Spinal Cord Injury Market Report and Forecast 2024-2032
Spinal Cord Injury Market Outlook
The spinal cord injury market size was valued at USD 5.2 billion in 2023, driven by rising incidence of injuries. The market size is anticipated to grow at a CAGR of 5.3% during the forecast period of 2024-2032 to achieve a value of USD 8.3 billion by 2032.
Spinal Cord Injury: Introduction
Spinal cord injury (SCI) involves damage to the spinal cord that results in a loss of function, such as mobility or sensation. The severity depends on the location and extent of the injury. SCIs can be traumatic, caused by accidents or violence, or non-traumatic, due to diseases or degeneration. Symptoms vary but can include paralysis, loss of sensation, and dysfunction in bodily systems. Treatment focuses on preventing further injury and enabling patients to live independently.
Key Trends in the Spinal Cord Injury Market
There's growing awareness about the benefits of early treatment for spinal cord injuries, which is driving the market forward. Prompt intervention is recognized for improving outcomes and reducing long-term complications.
The market is also being fueled by an increasing incidence of spinal cord injuries. Factors contributing to this rise include road accidents, falls, and sports injuries. The growing popularity of extreme sports activities across the globe is also noted as a contributing factor to the increased incidence of acute spinal cord injuries.
Advancements in medical technology are playing a crucial role in the treatment and rehabilitation of spinal cord injuries. Innovative treatments and rehabilitation techniques are improving outcomes and quality of life for patients.
There's a growing focus on not just acute care but also on the long-term rehabilitation and support for spinal cord injury patients. This includes physical therapy, occupational therapy, and the use of assistive devices to enhance mobility and independence.
Similar to other healthcare sectors, the spinal cord injury market is also witnessing the integration of digital health solutions. This includes tele-rehabilitation, remote monitoring, and the use of apps and platforms for patient support and community building.
Spinal Cord Injury Market Segmentation
Market Breakup by Injury Type
- Complete Spinal Cord Injury
- Incomplete Spinal Cord Injury
- Corticosteroid
- Surgery
- Spinal Traction
- Hospitals
- Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
North America is often seen as a leader in spinal cord injury treatment and research, primarily due to substantial investments in healthcare infrastructure and research facilities. The region has a strong presence of key market players who invest heavily in R&D activities, leading to innovative treatment options and rehabilitation technologies. There is also a robust regulatory framework that supports the introduction and adoption of new therapies. Awareness campaigns and fundraising activities by non-profit organizations further contribute to a supportive environment for spinal cord injury patients.
Europe shows a strong commitment to spinal cord injury management through its well-developed healthcare systems and government-funded health services. The region is known for its rigorous research activities, with numerous collaborations between academic institutions and the healthcare industry. These efforts are often supported by substantial funding from government bodies and private entities. European regulations, while strict, are aimed at ensuring the safety and efficacy of spinal cord injury treatments, facilitating the introduction of advanced therapies in the market.
Japan is witnessing significant growth in the spinal cord injury market, driven by increasing healthcare expenditure and a growing awareness of advanced treatment options. Country is rapidly modernizing their healthcare infrastructure and investing in medical research. The region also benefits from a large patient pool and increasing government initiatives aimed at improving healthcare accessibility. However, the market is quite diverse, with varying levels of healthcare infrastructure and access to treatment options across different countries.
Spinal Cord Injury Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Novartis AG
- Tenax Therapeutics
- Accure Pharma
- Acorda Therapeutics
- Asterias Biotherapeutics
- ReNetX Bio.
- BioArctic AB
- BioTime, Inc
- InVivo Therapeutics
- Kringle Pharma
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
180 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Spinal Cord Injury Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Spinal Cord Injury Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2017-2032)
- 5.2 United States Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3.1 Germany Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3.2 France Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 5.4 Japan Spinal Cord Injury Epidemiology Forecast (2017-2032)
- 6 Spinal Cord Injury Market Overview – 7MM
- 6.1 Spinal Cord Injury Market Historical Value (2017-2023)
- 6.2 Spinal Cord Injury Market Forecast Value (2024-2032)
- 7 Spinal Cord Injury Market Landscape – 7MM
- 7.1 Spinal Cord Injury Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Spinal Cord Injury Product Landscape
- 7.2.1 Analysis by Diseases Type
- 7.2.2 Analysis by Drug Class
- 7.2.3 Analysis by Route of Administration
- 8 Spinal Cord Injury Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Spinal Cord Injury Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Spinal Cord Injury Market Segmentation – 7MM
- 11.1 Spinal Cord Injury Market by Injury Type
- 11.1.1 Market Overview
- 11.1.2 Complete Spinal Cord Injury
- 11.1.3 Incomplete Spinal Cord Injury
- 11.2 Spinal Cord Injury Market by Treatment Type
- 11.2.1 Market Overview
- 11.2.2 Corticosteroid
- 11.2.3 Surgery
- 11.2.4 Spinal Traction
- 11.3 Spinal Cord Injury Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Clinics
- 11.3.4 Others
- 11.4 Spinal Cord Injury Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.4 Japan
- 12 United States Spinal Cord Injury Market
- 12.1 Spinal Cord Injury Market Historical Value (2017-2023)
- 12.2 Spinal Cord Injury Market Forecast Value (2024-2032)
- 12.3 Spinal Cord Injury Market by Disease Type
- 12.4 Spinal Cord Injury Market by Treatment Type
- 13 EU-4 and United Kingdom Spinal Cord Injury Market
- 13.1 Spinal Cord Injury Market Historical Value (2017-2023)
- 13.2 Spinal Cord Injury Market Forecast Value (2024-2032)
- 13.3 Germany Spinal Cord Injury Market Overview
- 13.3.1 Spinal Cord Injury Market by Disease Type
- 13.3.2 Spinal Cord Injury Market by Treatment Type
- 13.4 France Spinal Cord Injury Market Overview
- 13.4.1 Spinal Cord Injury Market by Disease Type
- 13.4.2 Spinal Cord Injury Market by Treatment Type
- 13.5 Italy Spinal Cord Injury Market Overview
- 13.5.1 Spinal Cord Injury Market by Disease Type
- 13.5.2 Spinal Cord Injury Market by Treatment Type
- 13.6 Spain Spinal Cord Injury Market Overview
- 13.6.1 Spinal Cord Injury Market by Disease Type
- 13.6.2 Spinal Cord Injury Market by Treatment Type
- 13.7 United Kingdom Spinal Cord Injury Market Overview
- 13.7.1 Spinal Cord Injury Market by Disease Type
- 13.7.2 Spinal Cord Injury Market by Treatment Type
- 14 Japan Spinal Cord Injury Market
- 14.1 Spinal Cord Injury Market Historical Value (2017-2023)
- 14.2 Spinal Cord Injury Market Forecast Value (2024-2032)
- 14.2.1 Spinal Cord Injury Market by Disease Type
- 14.2.2 Spinal Cord Injury Market by Treatment Type
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 15.7 Analysis by Key Players
- 16 Grants Analysis
- 16.1 Analysis by year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Clinical Trials Analysis
- 17.1 Analysis by Trial Registration Year
- 17.2 Analysis by Trial Status
- 17.3 Analysis by Trial Phase
- 17.4 Analysis by Therapeutic Area
- 17.5 Analysis by Geography
- 18 Funding Analysis
- 18.1 Analysis by Funding Instances
- 18.2 Analysis by Type of Funding
- 18.3 Analysis by Funding Amount
- 18.4 Analysis by Leading Players
- 18.5 Analysis by Leading Investors
- 18.6 Analysis by Geography
- 19 Partnership and Collaborations Analysis
- 19.1 Analysis by Partnership Instances
- 19.2 Analysis by Type of Partnership
- 19.3 Analysis by Leading Players
- 19.4 Analysis by Geography
- 20 Supplier Landscape
- 20.1 Novartis AG
- 20.1.1 Financial Analysis
- 20.1.2 Product Portfolio
- 20.1.3 Demographic Reach and Achievements
- 20.1.4 Mergers and Acquisition
- 20.1.5 Certifications
- 20.2 Tenax Therapeutics
- 20.2.1 Financial Analysis
- 20.2.2 Product Portfolio
- 20.2.3 Demographic Reach and Achievements
- 20.2.4 Mergers and Acquisition
- 20.2.5 Certifications
- 20.3 Accure Pharma
- 20.3.1 Financial Analysis
- 20.3.2 Product Portfolio
- 20.3.3 Demographic Reach and Achievements
- 20.3.4 Mergers and Acquisition
- 20.3.5 Certifications
- 20.4 Acorda Therapeutics
- 20.4.1 Financial Analysis
- 20.4.2 Product Portfolio
- 20.4.3 Demographic Reach and Achievements
- 20.4.4 Mergers and Acquisition
- 20.4.5 Certifications
- 20.5 Asterias Biotherapeutics
- 20.5.1 Financial Analysis
- 20.5.2 Product Portfolio
- 20.5.3 Demographic Reach and Achievements
- 20.5.4 Mergers and Acquisition
- 20.5.5 Certifications
- 20.6 ReNetX Bio.
- 20.6.1 Financial Analysis
- 20.6.2 Product Portfolio
- 20.6.3 Demographic Reach and Achievements
- 20.6.4 Mergers and Acquisition
- 20.6.5 Certifications
- 20.7 BioArctic AB
- 20.7.1 Financial Analysis
- 20.7.2 Product Portfolio
- 20.7.3 Demographic Reach and Achievements
- 20.7.4 Mergers and Acquisition
- 20.7.5 Certifications
- 20.8 BioTime, Inc
- 20.8.1 Financial Analysis
- 20.8.2 Product Portfolio
- 20.8.3 Demographic Reach and Achievements
- 20.8.4 Mergers and Acquisition
- 20.8.5 Certifications
- 20.9 InVivo Therapeutics
- 20.9.1 Financial Analysis
- 20.9.2 Product Portfolio
- 20.9.3 Demographic Reach and Achievements
- 20.9.4 Mergers and Acquisition
- 20.9.5 Certifications
- 20.10 Dr. Reddy's Laboratories Ltd.
- 20.10.1 Financial Analysis
- 20.10.2 Product Portfolio
- 20.10.3 Demographic Reach and Achievements
- 20.10.4 Mergers and Acquisition
- 20.10.5 Certifications
- 20.11 Zydus Cadila
- 20.11.1 Financial Analysis
- 20.11.2 Product Portfolio
- 20.11.3 Demographic Reach and Achievements
- 20.11.4 Mergers and Acquisition
- 20.11.5 Certifications
- 20.12 AbbVie Inc.
- 20.12.1 Financial Analysis
- 20.12.2 Product Portfolio
- 20.12.3 Demographic Reach and Achievements
- 20.12.4 Mergers and Acquisition
- 20.12.5 Certifications
- 20.13 Vertex Pharmaceuticals Inc.
- 20.13.1 Financial Analysis
- 20.13.2 Product Portfolio
- 20.13.3 Demographic Reach and Achievements
- 20.13.4 Mergers and Acquisition
- 20.13.5 Certifications
- 20.14 Pfizer Inc.
- 20.14.1 Financial Analysis
- 20.14.2 Product Portfolio
- 20.14.3 Demographic Reach and Achievements
- 20.14.4 Mergers and Acquisition
- 20.14.5 Certifications
- 20.15 Kringle Pharma
- 20.15.1 Financial Analysis
- 20.15.2 Product Portfolio
- 20.15.3 Demographic Reach and Achievements
- 20.15.4 Mergers and Acquisition
- 20.15.5 Certifications
- 21 Spinal Cord Injury Market - Distribution Model (Additional Insight)
- 21.1 Overview
- 21.2 Potential Distributors
- 21.3 Key Parameters for Distribution Partner Assessment
- 22 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 23 Company Competitiveness Analysis (Additional Insight)
- 23.1 Very Small Companies
- 23.2 Small Companies
- 23.3 Mid-Sized Companies
- 23.4 Large Companies
- 23.5 Very Large Companies
- 24 Payment Methods (Additional Insight)
- 24.1 Government Funded
- 24.2 Private Insurance
- 24.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
